ClinicalTrials.gg
CompletedNCT00770913Updated Apr 18, 2012Results posted

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

A Phase 2/3 interventional study of E3810 and E3810 in Refractory Reflux Esophagitis, sponsored by Eisai Co., Ltd.. Completed at 54 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-04-18.

Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
337
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Esophagitis, Peptic with a site in Japan — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · Japan.

Enrollment
5th of 10
337 · median 331
Started
2008
with 1 other
Phase 2/3
Only one
of the 16
Registered
4th of 16
by date
Lead sponsor
2 of 16
Eisai Co., Ltd.

Among the 16 studies in Esophagitis, Peptic with a site in Japan, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is the only one in phase 2/3, and was the 4th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 16 studies in Esophagitis, Peptic with a site in Japan is open now. The open studies under Esophagitis, Peptic, anywhere →

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Esophagitis, Peptic with a site in Japan as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.

Read the detailed description

This is a multicenter, randomized, double-blinded study. The efficacy with E3810 20 mg once daily is compared with E3810 20 mg twice daily and 10 mg twice daily using endoscopic recovery. The frequency of adverse event, etc., will be compared among 3 groups for safety assessment.

03

Conditions studied

  • Refractory Reflux Esophagitis

Keywords

  • reflux esophagitis
  • rabeprazole
  • GERD
  • Japan
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have mucosal breaks (erosions, ulcers) on endoscopy and are diagnosed with reflux esophagitis.
  • Proton Pump Inhibitor standard dose-resistant reflux esophagitis.
  • Patients who are 20 years and older when is obtained.

Exclusion criteria

Exclusion Criteria:

  • Patients with a concurrent severe illness, serious heart disease, comorbid severe disease such as hematology, kidney disease, or liver disease.
  • Patients with .
  • Patients who are taking another trial drug or the interval between the end of treatment and screening is less than 12 weeks.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
337 participants (actual)

Study arms

  • Active comparator
    1

    Drug: E3810

  • Experimental
    2

    Drug: E3810

  • Experimental
    3

    Drug: E3810

Interventions

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    20 mg taken orally, once a day for 8 weeks.

    Also known as: Aciphex

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    10 mg, taken orally, twice a day for 8 weeks.

    Also known as: Aciphex

  • DrugE3810

    Drug pages: Rabeprazole · E-3810

    20 mg taken orally, twice a day for 8 weeks.

    Also known as: Aciphex

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)

    Grade N indicates a normal appearance of lower esophageal mucosa

    Time frame: 8 weeks

07

Results

Posted Apr 13, 2012
Limitations and caveats
In the Participant flow section, there is only one "Reason for Not Completed" per participant reported, even if there were multiple reasons.

Participant flow

This study was recruited at 71 centers in Japan during the period of 17-Oct-2008 to 12-Nov-2009.

Participant flow — Overall Study
MilestoneE3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg Twice Daily
Started113111113
Completed102103100
Not completed11813
Withdrew: Adverse event136
Withdrew: Refusal to continue participation645
Withdrew: Physician decision011
Withdrew: Protocol violation301
Withdrew: Incorrect drug was allocated100

Outcome measures

PrimaryPercentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)

Grade N indicates a normal appearance of lower esophageal mucosa

Time frame:
8 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)
Percentage of ParticipantsE3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg
Percentage of Participants With Healing Demonstrated Via Upper Gastrointestinal Endoscopy (Modified Los Angeles Classification: Grade N)58.878.477.0

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E3810 20 mg Once Daily—3/112 (2.7%)27/112 (24.1%)
E3810 10 mg Twice Daily—6/111 (5.4%)25/111 (22.5%)
E3810 20 mg—5/114 (4.4%)20/114 (17.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventE3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg
GastroenteritisInfections and infestations0/1121/1111/114
Putamen haemorrhageNervous system disorders0/1121/1110/114
Cardiac failureCardiac disorders0/1121/1110/114
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/1121/1110/114
DermatitisSkin and subcutaneous tissue disorders0/1121/1110/114
Tendon ruptureInjury, poisoning and procedural complications0/1121/1110/114
Intracranial aneurysmNervous system disorders1/1120/1110/114
PneumothoraxRespiratory, thoracic and mediastinal disorders1/1120/1110/114
Back painMusculoskeletal and connective tissue disorders1/1120/1110/114
CellulitisInfections and infestations0/1120/1111/114
Most frequent other events
Most frequent other events
EventE3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg
NasopharyngitisInfections and infestations8/1127/1114/114
Blood thyroid stimulating hormone increasedInvestigations3/1127/1117/114
DiarrhoeaGastrointestinal disorders2/1125/1111/114
Blood triglycerides increasedInvestigations5/1121/1111/114
ConstipationGastrointestinal disorders2/1123/1115/114
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders4/1122/1112/114
Alanine aminotransferase increasedInvestigations3/1120/1110/114

Baseline characteristics

Age Continuous
Age Continuous(years)E3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg Twice DailyTotal
Mean64.5 ± 13.965.5 ± 13.366.6 ± 13.865.5 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)E3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg Twice DailyTotal
Female535962174
Male575249158
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)E3810 20 mg Once DailyE3810 10 mg Twice DailyE3810 20 mg Twice DailyTotal
Asian110111111332
08

Study locations

54 sites
  • Nagakute, Aichi, Japan
  • Nagoya, Aichi, Japan
  • Abiko, Chiba, Japan
  • Kashiwa, Chiba, Japan
  • Yachiyo, Chiba, Japan
  • Chikushino, Fukuoka, Japan
  • Omuta, Fukuoka, Japan
  • Tagawa, Fukuoka, Japan
  • Koriyama, Fukushima, Japan
  • Hashima, Gifu, Japan
  • Maebashi, Gunma, Japan
  • Asahikawa, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Itami, Hyogo, Japan
  • Nishinomiya, Hyogo, Japan
  • Hitachi, Ibaraki, Japan
  • Takamatsu, Kagawa, Japan
  • Kirishima, Kagoshima, Japan
  • Kawasaki, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Ishinomaki, Miyagi, Japan
  • Yamatokoriyama, Nara, Japan
  • Beppu, Oita, Japan
  • Hirakata, Osaka, Japan
  • Karatsu, Saga, Japan
  • Kusatsu, Shiga, Japan
  • Izumo, Shimane, Japan
  • Matsue, Shimane, Japan
  • Fujieda, Shizuoka, Japan
  • Hamamatsu, Shizuoka, Japan
  • Shimada, Shizuoka, Japan
  • Ohtawara, Tochigi, Japan
  • Bunkyo, Tokyo, Japan
  • Itabashi, Tokyo, Japan
  • Setagaya, Tokyo, Japan
  • Shinagawa, Tokyo, Japan
  • Shinjuku, Tokyo, Japan
  • Hofu, Yamaguchi, Japan
  • Shimonoseki, Yamaguchi, Japan
  • Akita, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Hiroshima, Japan
  • Kagoshima, Japan
  • Kouchi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Nagasaki, Japan
  • Oita, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Saga, Japan
  • Shizuoka, Japan
  • Yamagata, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Oct 2008
Primary completionActual
Nov 2009
CompletionActual
Mar 2010
Results first posted
Apr 13, 2012
Last update
Apr 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00770913
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Oct 10, 2008
Start date
Oct 2008
Primary completion
Nov 2009
Completion
Mar 2010
Results posted
Apr 13, 2012
Last update
Apr 18, 2012

Study contacts

Tomoki Kubota
study director · New Product Development Dept., Clinical Research Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rabeprazole · E-3810

Start the discussion